Done Global Execs Jailed for Adderall Scheme; FDA Warns on Ketamine

Two executives from the telehealth provider Done Global were sentenced to prison for their roles in an alleged $90 million scheme involving amphetamine/dextroamphetamine salts, commonly known as Adderall. The Justice Department announced the sentencing, detailing the operation that involved prescribing controlled substances without adequate medical supervision. This case highlights the ongoing scrutiny of telehealth platforms and their prescription practices.

In parallel, the U.S. Food and Drug Administration (FDA) issued a new safety warning concerning the use of ketamine, particularly in non-medical settings. The agency cautioned about the risks associated with ketamine when used for wellness purposes, emphasizing potential adverse effects and the importance of medical oversight. The FDA's updated guidance aims to protect public health by clarifying appropriate uses and highlighting dangers of misuse.

The broader context of these events touches upon concerns within the wellness industry, where some practices have been described as cult-like. The intersection of mental health treatments, prescription drug accessibility, and unregulated wellness trends presents significant public health challenges. Regulatory bodies like the FDA and law enforcement agencies are increasingly focused on ensuring patient safety and preventing exploitation within these rapidly evolving sectors.